In our prior work, we identified the co-expression of three predominant SLCs important in glutamine metabolism—namely, SLC1A5, SLC7A5, and SLC3A2—and that these are significantly overexpressed in aggressive luminal BC subgroups and are associated with poor outcome [7]. Here, SLC3A2 is linked to breast cancer.